Biologics And Clinical Immunology Cohort at Sinai
This observational study at Mount Sinai aims to create a registry of patients receiving biologic medications or immune modulators for immunological or autoimmune diseases, or primary immune deficiency. The researchers want to understand how these treatments affect your health over time. They will collect information like your demographics, immune system details, treatment history, and medical records. This will help them learn more about how these treatments work and how to make them more effective. You can join if you are 12 years or older, can give informed consent, receive medical care at Mount Sinai, and are either taking a biologic medication or immune modulator, or are considered a comparison participant by the study team. The main goal is to establish this registry and track information for at least 3 years.
- Study design
- This is an observational study planning to enroll 800 participants. It is not a treatment study but rather collects information about your existing medical care.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Information will be collected and tracked for at least 3 years as part of the registry.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Biologics And Clinical Immunology Cohort at Sinai
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Rachel Miller · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Biologics and Clinical Immunology Registry3 years
Establish a bioregistry of patients receiving biologic therapy as part of their standard treatment at the Mount Sinai Therapeutic Infusion Center and affiliated practices. The approach is twofold. The first component is to establish a robust and flexible biorepository and database that includes demographic, immunologic, exposure and clinical records, and can facilitate research across disciplines, and across other registries affiliated with Mount Sinai. The second component is to address specific key research questions focused on using novel diagnostics to increase the effectiveness of biologic treatment.